Attenuated in vitro coronary arteriolar vasorelaxation to insulin-like growth factor I in experimental hypercholesterolemia.

Insulin and insulin-like growth factor (IGF) 1 affect coronary vasoactivity. Experimental hypercholesterolemia is associated with coronary atherogenesis and altered vasomotor regulation. Because the IGF axis is altered during atherogenesis, we postulated that experimental hypercholesterolemia is associated with an altered coronary vasoactive response to IGF-1 in vitro. Coronary arteries and arterioles from pigs fed either a normal or high-cholesterol diet for 10 weeks were contracted with endothelin-1 and relaxed with cumulative concentrations of insulin or IGF-1 (10(-12) to 10(-7) mol/L). Control arterioles were also incubated with the nitric oxide synthase inhibitor 10(-4) mol/L N(G)-monomethyl-L-arginine (L-NMMA) or the potassium channel blocker 10(-2) mol/L tetraethylammonium (TEA), contracted with endothelin-1, and relaxed with insulin or IGF-1. Experimental hypercholesterolemia (1) increased serum cholesterol (9.5+/-1.0 versus 1.9+/-0.08 mmol/L; P<0.0001), (2) caused coronary arterial and arteriolar endothelial dysfunction in vitro (attenuated vasorelaxation to bradykinin), (3) did not alter the epicardial response to either insulin (P=0.80) or IGF-1 (P=0.12), and (4) significantly attenuated the arteriolar response to IGF-1 (maximal relaxation of 79+/-6% versus 42+/-8%; P=0.01) but not insulin (43+/-6% versus 53+/-7%; P=0.99). Control arteriolar vasorelaxation to IGF-1 was attenuated by both L-NMMA (P<0.001) and TEA (P=0.01), whereas only L-NMMA attenuated insulin (P<0.001). Staining for IGF-1 and IGF binding protein 2 was increased (P<0.05) in arterioles of cholesterol-fed pigs. IGF-1 and insulin are therefore coronary arteriolar vasorelaxants through different mechanisms. Experimental hypercholesterolemia is associated with resistance to the coronary arteriolar vasorelaxing effects of IGF-1 but not insulin, in conjunction with increased ligand and binding-protein expression. The IGF axis may contribute to the altered coronary vasoactivity in hypercholesterolemia.

[1]  R. Schwartz,et al.  Coronary artery apoptosis in experimental hypercholesterolemia. , 1999, Atherosclerosis.

[2]  R. Rizza,et al.  Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. , 1998, Hypertension.

[3]  J. Dunbar,et al.  Regional blood flow dynamics in response to insulin and IGF-1 in diabetic animals. , 1998, Clinical and experimental hypertension.

[4]  R. Schwartz,et al.  Acute endothelin-receptor inhibition does not attenuate acetylcholine-induced coronary vasoconstriction in experimental hypercholesterolemia. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[5]  R. Schwartz,et al.  Enhanced endothelin-B-receptor-mediated vasoconstriction of small porcine coronary arteries in diet-induced hypercholesterolemia. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[6]  R. Schwartz,et al.  Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. , 1997, Circulation.

[7]  K. Kurokawa,et al.  Modulation of renal hemodynamics by IGF-1 is absent in spontaneously hypertensive rats. , 1997, Kidney international.

[8]  R. Schwartz,et al.  The effect of basic fibroblast growth factor on coronary vascular tone in experimental hypercholesterolemia in vivo and in vitro , 1997, Coronary artery disease.

[9]  H. Kontos,et al.  Arginine analogues inhibit responses mediated by ATP-sensitive K+ channels. , 1996, The American journal of physiology.

[10]  P. Cohen,et al.  The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. , 1996, Endocrinology and metabolism clinics of North America.

[11]  D. Clemmons,et al.  Regulation of insulin‐like growth factor (IGF) binding protein‐2 synthesis and degradation by platelet‐derived growth factor and the IGFs is enhanced by serum deprivation in vascular smooth muscle cells , 1995, Journal of cellular physiology.

[12]  D. Clemmons,et al.  Porcine aortic smooth muscle cells secrete a serine protease for insulin-like growth factor binding protein-2. , 1995, Circulation research.

[13]  K. Kurokawa,et al.  Insulin nonattenuation of vasoactive agent-induced responses in mesangial cells from spontaneously hypertensive rats. , 1995, Kidney international.

[14]  R. Cohen,et al.  Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. , 1994, The American journal of physiology.

[15]  C. Pepine,et al.  Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? , 1994, Circulation.

[16]  E. Feldman,et al.  Regulation of insulin‐like growth factor binding protein synthesis and secretion in human retinal pigment epithelial cells , 1994, Journal of cellular physiology.

[17]  V. Fuster,et al.  Circulating and Tissue Endothelin Immunoreactivit in Hypercholesterolemic Pigs , 1993, Circulation.

[18]  J. Forrester,et al.  Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation. Evidence for local bioactivity. , 1992, The Journal of clinical investigation.

[19]  C. Conover.  A unique receptor-independent mechanism by which insulinlike growth factor I regulates the availability of insulinlike growth factor binding proteins in normal and transformed human fibroblasts. , 1991, The Journal of clinical investigation.

[20]  P. Fu,et al.  Enzymatic determination of total serum cholesterol. , 1974, Clinical chemistry.